GlassScriptPhysician profile
Xuecheng Wang
NPI 1679531594
$2,904.77
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,638 · 2020: $267.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $793.18 | 2019-2020 | |
| Glaxosmithkline, LLC. | $340.05 | 2019 | |
| Gilead Sciences, INC. | $307.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $293.12 | 2019 | |
| Amgen INC. | $279.32 | 2019-2020 | |
| Pfizer INC. | $269.76 | 2019 | |
| Novo Nordisk INC | $150.41 | 2019 | |
| Radius Health, INC. | $121.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $113.30 | 2019 | |
| Sanofi Pasteur INC. | $112.16 | 2019 | |
| Lilly USA, LLC | $83.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xuecheng Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.